Development and Evaluation of Iodinated Tracers Targeting Amyloid Plaques for SPECT Imaging

Kung, Mei‐Ping; Zhuang, Zhi‐Ping; Hou, Cathy; Kung, Hank F.

doi:10.1385/jmn:24:1:049

Cited by 21 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…144 Radiolabeled bombesin and its derivatives have been explored for cancer SPECT imaging. 138 Radiolabeled peptide conjugates for SPECT imaging of apoptosis, 140 amyloid plaques, 145 and tumor protein metabolism 138 have been developed.…”

Section: Nuclear Imaging Modalitiesmentioning

confidence: 99%

Whole animal imaging

Sandhu

Solorio

Broome

et al. 2010

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

Translational research plays a vital role in understanding the underlying pathophysiology of human diseases, and hence development of new diagnostic and therapeutic options for their management. After creating an animal disease model, pathophysiologic changes and effects of a therapeutic intervention on them are often evaluated on the animals using immunohistologic or imaging techniques. In contrast to the immunohistologic techniques, the imaging techniques are noninvasive and hence can be used to investigate the whole animal, oftentimes in a single exam which provides opportunities to perform longitudinal studies and dynamic imaging of the same subject, and hence minimizes the experimental variability, requirement for the number of animals, and the time to perform a given experiment. Whole animal imaging can be performed by a number of techniques including x-ray computed tomography, magnetic resonance imaging, ultrasound imaging, positron emission tomography, single photon emission computed tomography, fluorescence imaging, and bioluminescence imaging, among others. Individual imaging techniques provide different kinds of information regarding the structure, metabolism, and physiology of the animal. Each technique has its own strengths and weaknesses, and none serves every purpose of image acquisition from all regions of an animal. In this review, a broad overview of basic principles, available contrast mechanisms, applications, challenges, and future prospects of many imaging techniques employed for whole animal imaging is provided. Our main goal is to briefly describe the current state of art to researchers and advanced students with a strong background in the field of animal research.

show abstract

Section: Nuclear Imaging Modalitiesmentioning

confidence: 99%

Whole animal imaging

Sandhu

Solorio

Broome

et al. 2010

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

show abstract

“…Among the caveats of this imaging approach is that PiB is labeled with C-11, therefore requiring a cyclotron in situ, and limiting its clinical application. The development of specific F-18 [98], I-123 [176], or Tc-99m [177] labeled Aβ ligands will allow widespread application of the technique, the same way FDG is presently applied for cancer studies. Novel F-18 ligands are already being tested in phase I clinical studies [178,179].…”

Section: The Art Of Lossmentioning

confidence: 99%

The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias

et al. 2008

View full text Add to dashboard Cite

Molecular neuroimaging based on annihilation radiation tomographic (ART) techniques such as positron emission tomography (PET), in conjunction with related biomarkers in plasma and cerebrospinal fluid (CSF), are proving valuable in the early and differential diagnosis of Alzheimer's disease (AD). With the advent of new therapeutic strategies aimed at reducing beta-amyloid (Abeta) burden in the brain to potentially prevent or delay functional and irreversible cognitive loss, there is increased interest in developing agents that allow assessment of Abeta burden in vivo. Abeta burden as assessed by molecular imaging matches histopathological reports of Abeta plaque distribution in aging and dementia and appears more accurate than FDG for the diagnosis of AD. Abeta imaging is also a very powerful tool in the differential diagnosis of AD from fronto-temporal dementia (FTD). Although Abeta burden as assessed by PET does not correlate with measures of cognitive decline in AD, it does correlate with memory impairment and rate of memory decline in mild cognitive impairment (MCI) and healthy older subjects. Approximately 30% of asymptomatic controls present cortical (11)C-PiB retention. These observations suggest that Abeta deposition is not part of normal ageing, supporting the hypothesis that Abeta deposition occurs well before the onset of symptoms and is likely to represent preclinical AD. Further longitudinal observations are required to confirm this hypothesis and to better elucidate the role of Abeta deposition in the course of Alzheimer's disease.

show abstract

“…Neuroimaging should be obtained to identify vascular contributions to the dementia syndrome and other intracranial pathology. Functional imaging with positron emission tomography (PET) or single photon emission computed tomography (SPECT) is helpful particularly when clinical features are ambiguous [18][19][20][21][22][23][24][25][26][27]. Although these techniques are valuable, they remain nonetheless insufficient to unambiguously assess the disease and the clinical criteria that have now been developed by neurologists and neuropsychologists often lead to an approximate 90% accuracy.…”

Section: Clinical Diagnosismentioning

confidence: 99%

Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

Ziani-Cherif¹,

Mostefa‐Kara²,

Brixi-Gormat

2006

CPD

View full text Add to dashboard Cite

Alzheimer disease (AD) is characterized by excessive deposition of amyloid beta-peptides (Abeta peptides) in the form of senile plaques as well as neurofibrillary tangles (NFTs) in the brain. In the amyloidogenic pathway, the amyloid-beta precursor protein (APP) is cleaved by beta-secretase first, followed by gamma-secretase cleavage producing therefore Abeta. This review summarizes the recent findings in the AD field and focuses on the different gamma-secretase inhibitors that have been developed as a therapeutic approach toward AD.

show abstract

Development and Evaluation of Iodinated Tracers Targeting Amyloid Plaques for SPECT Imaging

Cited by 21 publications

References 18 publications

Whole animal imaging

Whole animal imaging

The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias

Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

Contact Info

Product

Resources

About